Clinical trials: Temporal Arteritis
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cells Arteritis
Biomarkers in Giant Cells Arteritis
Giant cells arteritis or Horton disease is a vasculitis that affects great vessels. This is the most frequent vasculitis of the population over the age of 50.
- Trial name
- BioACG (NCT02844023)
- Testing
- Clinical evaluation, Paraclinical evaluation, Imaging
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Giant Cell Arteritis
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II.
- Trial name
- NCT00004686
- Testing
- methotrexate, prednisone
- Volunteers
- 300 people
- Sponsor
- The Cleveland Clinic
Giant Cell Arteritis
FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment
Giant cell arteritis (GCA) affects large and medium sized vessels. Large vessel-GCA (LV-GCA) affecting aorta and/or its main branches is seen a) together with temporal arteritis (AT-GCA), b) as isolated LV-GCA but also c) with…
- Trial name
- NCT03285945
- Testing
- PET3, PET10
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Takayasu's Arteritis, Giant Cell Arteritis
Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
The purpose of this study is to evaluate the ability of contrast enhanced carotid ultrasound to serve as an indicator of disease activity in patients with Takayasu's arteritis or Giant Cell arteritis and to determine if patients…
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Arteritis, Vasculitis
- Trial name
- NCT01795456
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Giant Cell Arteritis
Giant Cell Arteritis and PET Scan (GAPS) Study
Giant cell arteritis (GCA) is a medium to large vessel vasculitis with a predilection for the superficial cranial and intrathoracic arteries.
- Trial name
- NCT02771483
- Where
- Australia
- Volunteers
- 64 people
- Sponsor
- Royal North Shore Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- NCT04335747
- Testing
- COVID-19 infection
- Where
- Denmark
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Salome Kristensen
Giant Cell Arteritis (GCA)
Cardiac Involvement in Patients With Giant Cell Arteritis
This prospective observational study aims to investigate whether patients with newly diagnosed giant cell arteritis (GCA) show signs of cardiac involvement.
- Trial name
- NCT07031284
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University Hospital, Bonn
Temporal Arteritis
Aetiology of TemporaL Arteritis Study
Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis.
- Trial name
- ATLAS (NCT02584517)
- Sponsor
- University of Oxford
Giant Cell Arteritis
Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis
The factors underlying the large interindividual variability in response to glucocorticoids in Giant Cell Arteritis are poorly understood.
- Trial name
- PREDICORT (NCT01400464)
- Testing
- Prednisone therapy and pharmacokinetic
- Where
- 12 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
Giant Cell Arteritis
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries.
- Trial name
- SPARTA (NCT05854927)
- Testing
- 3D T1 MRI sequences injected with fat saturation and black blood
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Giant Cell Arteritis (GCA)
Disease Activity Monitoring in Patients With Giant Cell Arteritis Study
Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation.
- Trial name
- DiAcMo (NCT07552636)
- Where
- 7 sites in Denmark
- Volunteers
- 175 people
- Sponsor
- University of Aarhus
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Giant Cell Arteritis (GCA), Doppler Ultrasound
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50.
- Trial name
- Halo-A (NCT07060274)
- Testing
- Doppler Ultrasound
- Where
- 6 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier le Mans
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Giant Cell Arteritis (GCA)
The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.
Giant cell arteritis (GCA) is the most common vasculitis in the elderly and is usually treated with long-term corticosteroid therapy. Many patients experience relapses and treatment-related side effects.
- Trial name
- NCT07246577
- Where
- Sweden
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Giant Cell Arteritis
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA).
- Trial name
- NCT03244709
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Hospital of Prato
Giant Cell Arteritis
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.
- Trial name
- NCT00305539
- Testing
- adalimumab
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Large Vessel Vasculitis, Takayasu Arteritis
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are…
- Conditions
- Large Vessel Vasculitis, Takayasu Arteritis, Giant Cell Arteritis (GCA)
- Trial name
- LAVA-FLOW (NCT07628075)
- Testing
- [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London